Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus ESTROGENIC SUBSTANCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus ESTROGENIC SUBSTANCE.
DIETHYLSTILBESTROL vs ESTROGENIC SUBSTANCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
Estrogens bind to and activate nuclear estrogen receptors (ERα and ERβ), leading to gene transcription and regulation of reproductive tissues and secondary sexual characteristics.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
0.3 to 1.25 mg orally once daily; 25 to 100 mcg transdermal patch applied twice weekly; 0.5 to 2 mg vaginal cream daily for 3 weeks then 1 week off.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 13-27 hours for endogenous estrogens, with clinically therapeutically relevant metabolites having half-lives up to 24-36 hours, allowing once-daily dosing.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Primarily renal as glucuronide and sulfate conjugates; approximately 60-80% excreted in urine, 10-30% in feces via biliary elimination.
Category C
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."